Paul Herzich - Dec 2, 2022 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
Chief Technology Officer
Signature
/s/ David Tyronne Howton as attorney-in-fact for Paul Herzich
Stock symbol
SLDB
Transactions as of
Dec 2, 2022
Transactions value $
$0
Form type
4
Date filed
12/5/2022, 04:48 PM
Next filing
Dec 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLDB Stock Option (Right to Buy) Award $0 +57.9K $0.00 57.9K Dec 2, 2022 Common Stock 57.9K $6.77 Direct F1
transaction SLDB Restricted Stock Units Award $0 +29K $0.00 29K Dec 2, 2022 Common Stock 29K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary.
F2 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").
F3 The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.